CLPT icon

ClearPoint Neuro

16.72 USD
-0.73
4.18%
At close Feb 21, 4:00 PM EST
After hours
16.51
-0.21
1.26%
1 day
-4.18%
5 days
-8.08%
1 month
-9.23%
3 months
50.77%
6 months
40.27%
Year to date
7.59%
1 year
132.55%
5 years
202.90%
10 years
328.72%
 

About: ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, and ClearPoint Therapeutic Solutions.

Employees: 107

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,361% more call options, than puts

Call options by funds: $7.09M | Put options by funds: $485K

100% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 11

53% more capital invested

Capital invested by funds: $76.6M [Q3] → $117M (+$40.3M) [Q4]

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

13% more funds holding

Funds holding: 78 [Q3] → 88 (+10) [Q4]

2.8% more ownership

Funds ownership: 24.76% [Q3] → 27.56% (+2.8%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$20
20%
upside
Avg. target
$25
50%
upside
High target
$30
79%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
B. Riley Securities
Neil Chatterji
100% 1-year accuracy
2 / 2 met price target
20%upside
$20
Buy
Maintained
28 Jan 2025
Lake Street
Frank Takkinen
55% 1-year accuracy
11 / 20 met price target
79%upside
$30
Buy
Maintained
21 Jan 2025

Financial journalist opinion

Based on 4 articles about CLPT published over the past 30 days

Neutral
Accesswire
1 week ago
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 fourth quarter and full year results on Wednesday, February 26th, at 4:30 p.m.
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
Neutral
Accesswire
1 week ago
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula
SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for the SmartFlow Neuro Cannula. The SmartFlow Cannula was previously cleared under the Medical Device Directive 93/42/EEC (MDD) and has now successfully achieved the more rigorous EU MDR certification well ahead of the 2027 deadline for Class III devices.
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula
Positive
Zacks Investment Research
3 weeks ago
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
Neutral
Accesswire
3 weeks ago
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its ClearPoint Navigation Software Version 3.0. "As we prepare for the wave of new patients that will be treated with cell and gene therapies in the years ahead, it is crucial that ClearPoint helps healthcare providers be ready by providing simplified workflows, offering solutions to increase surgical capacity and expanding access to our hardware and software," commented Joe Burnett, President and CEO at ClearPoint Neuro.
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
Positive
Zacks Investment Research
1 month ago
ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains?
ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains?
Positive
Zacks Investment Research
2 months ago
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
Neutral
Accesswire
3 months ago
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
Negative
Seeking Alpha
3 months ago
ClearPoint Neuro: Near-Term Volatility Is No Concern
ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity of growth initiatives. ClearPoint's margins are improving, and cash burn is minimal, which should ease concerns about dilution.
ClearPoint Neuro: Near-Term Volatility Is No Concern
Neutral
Seeking Alpha
3 months ago
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.20 per share a year ago.
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates
Charts implemented using Lightweight Charts™